Skip to main content
TipRanks
Go Ultimate75% OFF

Zivo Bioscience (ZIVO) AI Stock Analysis

45 Followers
ZIVO

Zivo Bioscience

(Other OTC:ZIVO)

Select Model
Rating:33.5Underperform
Action:N/A
Date:02/01/25

Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company's negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.

Positive Factors
Revenue GrowthThe significant revenue growth trajectory indicates strong demand for Zivo's algal bioactive compounds, supporting long-term market potential and business expansion.
Negative Factors
Financial InstabilityNegative equity and insolvency highlight severe financial instability, threatening Zivo's operational continuity and necessitating immediate restructuring for long-term viability.

Zivo Bioscience (ZIVO) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%ZIVO-52.79%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$22.40M
Dividend Yield
―
Average Volume (3M)
1,037
Price to Earnings (P/E)
-4.8
Beta (1Y)
0.47
Revenue Growth
-100.00%
EPS Growth
47.24%
Country
US
Employees
7
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Zivo Bioscience Business Overview & Revenue Model

Company Description

ZIVO Bioscience, Inc. is a research and development firm that specializes in the creation and commercialization of natural bioactive compounds. These unique ingredients, derived from its proprietary algae cultures, are licensed and sold to manufactur...

How the Company Makes Money

Zivo Bioscience makes money by developing and licensing its proprietary algal bioactive compounds to companies in the nutrition, wellness, and animal health industries. The company's revenue streams largely consist of licensing fees, royalties, and c...

Zivo Bioscience Technical Analysis

Technical Analysis SentimentNeutral
Last Price5.76

Price Trends

50DMA5.27Positive
100DMA4.79Positive
200DMA5.32Positive

Market Momentum

MACD0.20Positive
RSI45.69Neutral
STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIVO, the sentiment is Neutral. The current price of 5.76 is below the 20-day moving average (MA) of 7.01, above the 50-day MA of 5.27, and above the 200-day MA of 5.32, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ZIVO.

Zivo Bioscience Risk Analysis

Zivo Bioscience disclosed 26 risk factors in its most recent earnings report. Zivo Bioscience reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Zivo Bioscience Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ZIVO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PASGPASG46Neutral$13.68M-0.41-377.94%――28.49%
CTXRCTXR43Neutral$14.69M-0.25-67.15%――57.48%
JSPRJSPR42Neutral$15.17M-0.29-618.87%――73.74%
PTNPTN41Neutral$11.10M-1.19-115.00%―――
ZIVOZIVO34Underperform$22.40M-4.84133.19%―-100.00%47.24%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%ZIVOPTNCTXRPASGJSPRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ZIVO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ZIVOZivo Bioscience 5.76-6.14-51.60%
PTNPalatin Technologies, Inc.6.23-6.50-51.06%
CTXRCitius Pharma0.54-0.40-42.78%
PASGPassage Bio, Inc.4.25-4.73-52.67%
JSPRJasper Therapeutics, Inc.13.68-40.02-74.52%

Zivo Bioscience Corporate Events

Executive/Board Changes

Zivo Bioscience CFO Resigns, Interim Successor Appointed

Negative
Dec 23, 2025

On December 19, 2025, Zivo Bioscience’s Chief Financial Officer, Keith R. Marchiando, resigned effective immediately and agreed to end his employment with the company on December 31, 2025, under a separation agreement that provides him with his curre...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Feb 01, 2025